Group 1 - The company announced the approval of a synthetic biology manufacturing project in Xinjiang, with a total investment of 1 billion yuan, to be constructed in three phases [2][5] - The project aims to meet market demand, overcome capacity and efficiency bottlenecks, and achieve technological upgrades and cost control [2][6] - The project aligns with the encouraging industrial policies of the western region, allowing the company to benefit from local tax incentives and meet green development requirements [2][6] Group 2 - The company specializes in the animal health sector, focusing on the research, production, and sales of veterinary drugs, feed, and additives [4][8] - The company has achieved full coverage in the top 10 of the national pig farming industry and has established stable partnerships with many large domestic farming enterprises [5][8] - The projected sales revenue for 2024 is 1.2 billion yuan, representing a year-on-year growth of 17.71% [5][8] - The company currently has a production capacity of 2,000 tons for Tylosin and 840 tons for Tiamulin [5][8]
投资10亿！A股兽药龙头，生物制造项目落地新疆！
Xin Lang Cai Jing·2026-02-06 11:20